Statins May Augment Outcomes During CD19 CAR-T Therapy for R/R LBCL

Concurrent statin therapy was associated with significantly improved survival outcomes and reduced neurotoxicity in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) receiving CD19-directed chimeric antigen receptor T-cell (CAR T) therapy, a retrospective analysis observes.¹

In the Blood Immunology & Cellular Therapy study of 84 patients with LBCL treated with FDA-approved CAR T therapies between January 2018 and May 2024, patients in the statin-exposed cohort (n = 32) had a median progression-free survival (PFS) that was not reached, compared with 16.7 months (95% CI, 4.6-28.9) reached in the 52 non-exposed patients (P =.026).

Median overall survival (OS) was similarly not reached in statin-exposed patients vs 17.8 months (95% CI, 10.3-25.3) in those not receiving statins (P =.032). At last follow-up, fewer patients in the statin cohort had died (21.9% vs 42.3%), underscoring a clinically meaningful difference in disease control.¹

These findings suggest that statins, agents already widely used for cardiovascular risk reduction, may exert immunomodulatory effects capable of augmenting the antitumor activity of CAR T therapy in hematologic malignancies. The authors called for prospective trials to assess whether statin initiation or continuation should be considered as adjunctive management in patients undergoing CAR T infusion.

“These findings suggest that statin exposure, particularly to lipophilic statins, enhances the efficacy of CD19-directed CAR T,” wrote Ethan A. Burns, MD and colleagues. “If confirmed, this approach could represent a promising strategy to enhance the efficacy of CAR T therapy while reducing its associated toxicities.”

Safety and Toxicity Findings

Rates of any-grade cytokine release syndrome (CRS) were numerically lower in the statin cohort (75.0% vs 80.8%; P =.537), and rates of any-grade immune effector cell-associated neurotoxicity syndrome (ICANS) were also numerically lower (21.9% vs 34.6%; P =.220), though neither difference reached statistical significance. Median CRS grade was 1 in both groups, and median ICANS grade was similarly 1 in both cohorts.

Tocilizumab was administered in 43.7% of statin-exposed patients vs 63.4% of those without statin exposure (P =.079), representing a trend toward reduced immunosuppressive intervention that did not reach significance. Dexamethasone utilization followed a similar pattern (4

0.6% vs 53.8%; P =.21).

Statins: A Promising Adjunct?

R/R LBCL carries a poor prognosis, and 3 CD19-directed CAR-T products are currently approved by the FDA for this indication: axicabtagene ciloleucel (axi-cel; Yescarta), tisagenlecleucel (tisa-cel; Kymriah), and lisocabtagene maraleucel (liso-cel; Breyanzi).² Despite these advances, approximately half of treated patients experience disease progression within 2 years of infusion. Identifying modifiable factors that improve outcomes has therefore become a priority. T-cell exhaustion—a state of impaired effector function that limits sustained antitumor activity—is a key contributor to CAR T therapy failure.

Hydroxymethylglutaryl coenzyme A reductase inhibitors, otherwise known as statins, have well-established immunomodulatory and anti-inflammatory properties beyond their lipid-lowering effects. Preclinical data have demonstrated pro-apoptotic activity in lymphoma cell lines, and there is emerging evidence that statins attenuate T-cell exhaustion by modulating the tumor microenvironment.¹

The findings raise the question of whether statins could function as low-cost, broadly accessible adjuncts in the CAR T treatment paradigm. The plausible biologic rationale—reduced T-cell exhaustion, anti-inflammatory effects, and lymphoma-directed pro-apoptotic activity—provides mechanistic support for the survival signal observed. The trend toward reduced tocilizumab utilization in the statin group, while not statistically significant, may have clinical and resource-utilization implications if confirmed in larger studies.

However, the study emphasizes that routine initiation of statins solely for the purpose of improving CAR T outcomes cannot yet be recommended until validated in prospective, randomized clinical trials.

REFERENCES

1. Burns EA, Giese N, Mathur S, et al. Statin therapy with CD19-directed CAR-T therapy improves outcomes in relapsed or refractory large B-cell lymphoma. Blood Immunology & Cellular Therapy. 2026;2(1):100021. doi:10.1016/j.bict.2025.100021

2. Chen YJ, Abila B, Mostafa Kamel Y. CAR-T: What Is Next?. Cancers (Basel). 2023;15(3):663. Published 2023 Jan 21. doi:10.3390/cancers15030663